Literature DB >> 7250151

On the pharmacokinetics of domperidone in animals and man II. Tissue distribution, placental and milk transfer of domperidone in the Wistar rat.

M Michiels, R Hendriks, J Heykants.   

Abstract

Tissue distribution, placental transfer and transition into milk of the gastrokinetic drug domperidone were studied in the Wistar rat after i.v. or p.o. administration of the labelled compound at 2.5 mg/kg. Whole-body autoradiography and liquid scintillation counting were used to investigate the tissue localization of domperidone in pregnant and non-pregnant rats. In fasted rats, tissue levels were maximal within 15 minutes after either route. In non-fasted animals peak time occurred 30 minutes after oral treatment. Large amounts of radioactivity were present in the stomach, and in the bilious contents of the intestine. High activity was further detected in the liver, kidney, lung and some glandular tissues. After a rapid initial decrease radioactivity was eliminated with a half-life of 8-10 hours. Except for brain and testes, plasma levels were markedly lower than corresponding tissue levels. At 1 hour placental levels were 2-2.7 times higher and foetal concentrations 2.1-2.5 times lower than maternal plasma levels. The placentae and foetuses predominantly contained unchanged domperidone. At peak time only 0.2 (i.v.) and 0.08% (p.o.) of the dose crossed the placenta. Blood levels were always lower than milk concentrations. Preferentially metabolites were excreted with the milk. After a 20-hour suckling period of orally dosed dams, 0.2% of the dose was recovered in the combined tissues of 6 suckling pups.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7250151     DOI: 10.1007/BF03189514

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Nadolol: placental transfer and excretion in the milk of rats.

Authors:  J Dreyfuss; J M Shaw; T J Miller
Journal:  Toxicol Appl Pharmacol       Date:  1977-02       Impact factor: 4.219

2.  Differential effects of dopamine antagonists on prolactin secretion from cultured rat pituitary cells.

Authors:  C Denef; J J Follebouckt
Journal:  Life Sci       Date:  1978-08-07       Impact factor: 5.037

3.  Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.

Authors:  J M Van Nueten; C Ennis; L Helsen; P M Laduron; P A Janssen
Journal:  Life Sci       Date:  1978-08-07       Impact factor: 5.037

4.  On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man.

Authors:  W Meuldermans; R Hurkmans; E Swysen; J Hendrickx; M Michiels; W Lauwers; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

5.  Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat.

Authors:  D Cocchi; I Gil-Ad; M Parenti; E Stefanini; V Locatelli; E E Müller
Journal:  Neuroendocrinology       Date:  1980       Impact factor: 4.914

6.  On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.

Authors:  J Heykants; R Hendriks; W Meuldermans; M Michiels; H Scheygrond; H Reyntjens
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

7.  On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats.

Authors:  J Heykants; A Knaeps; W Meuldermans; M Michiels
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

8.  Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.

Authors:  A J Reyntjens; C J Niemegeers; J M Van Nueten; P Laduron; J Heykants; K H Schellekens; R Marsboom; A Jageneau; A Broekaert; P A Janssen
Journal:  Arzneimittelforschung       Date:  1978

9.  The antiemetic effects of domperidone, a novel potent gastrokinetic.

Authors:  C J Niemegeers; K H Schellekens; P A Janssen
Journal:  Arch Int Pharmacodyn Ther       Date:  1980-03
  9 in total
  13 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man.

Authors:  W Meuldermans; R Hurkmans; E Swysen; J Hendrickx; M Michiels; W Lauwers; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

3.  On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration.

Authors:  J Heykants; R Hendriks; W Meuldermans; M Michiels; H Scheygrond; H Reyntjens
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

4.  Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics.

Authors:  Tomotaka Shingaki; Yumiko Katayama; Takayoshi Nakaoka; Tadayuki Takashima; Kayo Onoe; Takashi Okauchi; Emi Hayashinaka; Yasuhiro Wada; Yilong Cui; Yasuyoshi Watanabe
Journal:  Pharm Res       Date:  2016-02-11       Impact factor: 4.200

5.  On the pharmacokinetics of domperidone in animals and man. I. Plasma levels of domperidone in rats and dogs. Age related absorption and passage through the blood brain barrier in rats.

Authors:  J Heykants; A Knaeps; W Meuldermans; M Michiels
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

Review 6.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Mosapride citrate increases postprandial glucagon-like peptide-1, insulin, and gene expression of sweet taste receptors.

Authors:  Daisuke Maruoka; Makoto Arai; Takeshi Tanaka; Kenichiro Okimoto; Arata Oyamada; Shoko Minemura; Masaru Tsuboi; Tomoaki Matsumura; Tomoo Nakagawa; Tatsuo Kanda; Tatsuro Katsuno; Fumio Imazeki; Osamu Yokosuka
Journal:  Dig Dis Sci       Date:  2014-07-10       Impact factor: 3.199

Review 8.  Domperidone. A review of its use in diabetic gastropathy.

Authors:  A Prakash; A J Wagstaff
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 9.  Models for placental transfer studies of drugs.

Authors:  P Bourget; C Roulot; H Fernandez
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

Review 10.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.